Literature DB >> 30468929

Risk Factors and Associated Complications of Symptomatic Venous Thromboembolism in Patients with Craniotomy for Meningioma.

Andrew Nunno1, Yan Li2, Thomas A Pieters1, James E Towner1, Tyler Schmidt1, Meichuanzi Shi1, Kevin Walter1, Yan Michael Li3.   

Abstract

OBJECTIVE: Patients undergoing surgical resection of meningioma are at increased risk for developing venous thromboembolism (VTE). The aim of this study was to assess occurrence of VTE in patients who underwent surgical resection of meningioma to determine risk factors and associated complications of VTE.
METHODS: The American College of Surgeons National Surgical Quality Improvement Project database from 2012 to 2015 was reviewed for patients who had undergone meningioma resection according to primary Current Procedural Terminology codes and International Classification of Diseases, Ninth Revision.
RESULTS: The study included 5036 patients with meningioma. Rate of VTE was 3.38%, with pulmonary embolism rate of 1.47% and deep venous thrombosis rate of 2.42%. During the first 30 days after surgery, patients with VTE had a mortality rate of 5.88% compared with 1.15% for patients without VTE. Multivariate binary logistic regression analysis determined 5 risk factors for VTE,: age ≥60 years, American Society of Anesthesiologists classification III, operative time ≥310 minutes, ventilator dependence, and preoperative transfusions. Univariate analysis revealed a number of complications significantly associated with VTE occurrence, including unplanned intubation, ventilator use for >48 hours, stroke, sepsis, septic shock, pneumonia, urinary tract infection, and transfusions.
CONCLUSIONS: Risk factors of VTE and associated complications were identified. Understanding these risk factors provides physicians with further insight in managing this subgroup of patients in a personalized fashion in the perioperative period to minimize the incidence and morbidity of VTE.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Craniotomy; Deep venous thromboembolism; Meningioma; NSQIP; Pulmonary embolism; Venous thromboembolism

Mesh:

Year:  2018        PMID: 30468929     DOI: 10.1016/j.wneu.2018.11.091

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Predictive risk factors for venous thromboembolism in neurosurgical patients: A retrospective analysis single center cohort study.

Authors:  Porntip Parmontree; Phanuwat Ketprathum; Teeraphat Ladnok; Supanut Meeaium; Thanyaras Thanaratsiriworakul; Ukrit Sonhorm
Journal:  Ann Med Surg (Lond)       Date:  2022-04-14

2.  Sepsis and septic shock after craniotomy: Predicting a significant patient safety and quality outcome measure.

Authors:  Jingwen Zhang; Yan Icy Li; Thomas A Pieters; James Towner; Kevin Z Li; Mohammed A Al-Dhahir; Faith Childers; Yan Michael Li
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

3.  Venous thromboembolic and hemorrhagic events after meningioma surgery: A single-center retrospective cohort study of risk factors.

Authors:  Nebojsa Lasica; Djula Djilvesi; Vladimir Papic; Mladen Karan; Bojan Jelaca; Jagos Golubovic; Filip Pajicic; Milica Medic-Stojanoska; Petar Vulekovic; Lukas Rasulic
Journal:  PLoS One       Date:  2022-08-16       Impact factor: 3.752

4.  microRNAs and Markers of Neutrophil Activation as Predictors of Early Incidental Post-Surgical Pulmonary Embolism in Patients with Intracranial Tumors.

Authors:  Julia Oto; Emma Plana; María José Solmoirago; Álvaro Fernández-Pardo; David Hervás; Fernando Cana; Francisco España; Andrea Artoni; Paolo Bucciarelli; Giorgio Carrabba; Silvia Navarro; Giuliana Merati; Pilar Medina
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

5.  Streamlining brain tumor surgery care during the COVID-19 pandemic: A case-control study.

Authors:  Regin Jay Mallari; Michael B Avery; Alex Corlin; Amalia Eisenberg; Terese C Hammond; Neil A Martin; Garni Barkhoudarian; Daniel F Kelly
Journal:  PLoS One       Date:  2021-07-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.